{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"9.6","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams \\[mg\\]) on Day 1 of each 21-day cycle.","id":"OG000","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until death (up to approximately 42 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}